Pfizer to Buy Remaining Shares of Trillium Therapeutics
Pfizer to Buy Remaining Shares of Trillium Therapeutics
DJ Pfizer to Buy Remaining Shares of Trillium Therapeutics
DJ辉瑞将收购延龄治疗公司剩余股份
By Dave Sebastian
戴夫·塞巴斯蒂安(Dave Sebastian)
Pfizer Inc. has agreed to buy shares it didn't already own in Trillium Therapeutics Inc., a company focused on developing therapies for cancer treatment, for an implied equity value of $2.26 billion.
辉瑞公司(Pfizer Inc.)已同意以22.6亿美元的隐含股权价值收购其尚未持有的Trillium治疗公司(Trillium Treateutics Inc.)的股份。Trillium Treeutics Inc.是一家专注于开发癌症治疗方法的公司。
The companies on Monday said Pfizer is paying $18.50 a share in cash. Trilium shares closed at $6.09 on Nasdaq on Friday.
两家公司周一表示，辉瑞将以每股18.50美元的现金支付。Trilium股价周五在纳斯达克收于6.09美元。
The deal would boost Pfizer's oncology category with the addition of immuno-therapeutics for hematological malignancies, they said.
他们说，这笔交易将增加针对血液恶性肿瘤的免疫疗法，从而提升辉瑞的肿瘤学类别。
Write to Dave Sebastian at dave.sebastian@wsj.com
写信给戴夫·塞巴斯蒂安(Dave Sebastian)，电子邮件：dave.sebastian@wsj.com
(END) Dow Jones Newswires
(完)道琼通讯社
August 23, 2021 06:58 ET (10:58 GMT)
2021年8月23日东部时间06：58(格林尼治标准时间10：58)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司